Citadel Advisors
SEEL

Citadel Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Citadel Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-37
Closed -$6.67K – 15643
2023
Q4 		$6.67K Sell
37
-1
-3% -$492 ﹤0.01% 13338
2023
Q3 		$26.7K Buy
38
+19
+100% +$81.5K ﹤0.01% 12381
2023
Q2 		$88.5K Sell
19
-1
-5% -$3.47K ﹤0.01% 11108
2023
Q1 		$54K Sell
20
-43
-68% -$126K ﹤0.01% 12058
2022
Q4 		$164K Buy
63
+1
+2% +$3.49K ﹤0.01% 10466
2022
Q3 		$245K Sell
62
-19
-23% -$74.7K ﹤0.01% 10016
2022
Q2 		$212K Buy
81
+9
+13% +$23.4K ﹤0.01% 10585
2022
Q1 		$230K Buy
72
+51
+243% +$219K ﹤0.01% 11194
2021
Q4 		$133K Buy
21
+14
+200% +$107K ﹤0.01% 12419
2021
Q3 		$67K Buy
7
+2
+40% +$17.2K ﹤0.01% 13190
2021
Q2 		$50K Sell
5
-7
-58% -$115K ﹤0.01% 13337
2021
Q1 		$238K Buy
+12
New +$140K ﹤0.01% 11353
2016
Q4 		– Hold
0
– -$4K – 7974
2016
Q3 		– Hold
0
– – – 7160
2016
Q2 		– Hold
0
– – – 6705
2016
Q1 		– Hold
0
– -$9K – 8192
2015
Q4 		– Hold
0
– – – 8314
2015
Q2 		– Hold
0
– -$30K – 9159
2015
Q1 		– Hold
0
– – – 7698
2014
Q4 		– Hold
0
– – – 8278
2014
Q3 		– Hold
0
– – – 7348
2014
Q2 		– Hold
0
– – – 6536
2014
Q1 		– Hold
0
– – – 7655
2013
Q4 		– Hold
0
– – – 6313
2013
Q3 		– Hold
0
– – – 6398
2013
Q2 		– Hold
0
– – – 5658

Other funds holding SEEL

WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return

Citadel Advisors's SEEL Position: Q1 2024 in Review

Citadel Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2024, closing a stake of 317 shares — an estimated $56.3K sold.

Citadel Advisors first reported a position in SEEL in Q1 2018 and held it in 15 quarters. The position peaked at $592K in Q1 2021. 29 funds tracked by Wall St. Rank hold SEEL as of Q1 2024.

  • Citadel Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 317 Seelos Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $56.3K.
  • Citadel Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
  • Citadel Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $592K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.